Press Release

Printer Friendly Version View printer-friendly version
<< Back

Histogenics Corporation to Host Investor Day on June 19, 2018

05/31/18

WALTHAM, Mass., May 31, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Histogenics will host its first Investor Day on Tuesday, June 19, 2018, in New York City. Members of Histogenics’ management team will provide a corporate overview and discuss the commercialization plan for NeoCart®, Histogenics’ lead investigational product, designed to rebuild a patient’s own knee cartilage to treat pain at the source and potentially prevent a patient’s progression to osteoarthritis. Histogenics’ management will be joined by leading orthopedic surgeons who will provide their clinical perspectives on NeoCart, as well as market access insights into today’s orthopedic marketplace.  The program will also include perspectives from a patient that received NeoCart in the Phase 3 clinical trial as well as additional content related to Histogenics’ technology platform including a discussion on tissue engineering and the biomechanics of cartilage tissue.

A live audio webcast of the presentation will be available via the “Investor Relations” page of Histogenics’ website, www.histogenics.com. A replay of the webcast will be archived on Histogenics’ website for approximately 45 days following the call.

Event Details 
 
Date:  Tuesday, June 19, 2018
Time:  8:15 a.m. — 11:30 a.m. ET 
Location:  New York City 


Speakers will include: 
   
Adam Gridley  President and Chief Executive Officer, Histogenics Corporation

Don Haut Chief Business Officer, Histogenics Corporation

Stephen Kennedy  Chief Operating Officer, Histogenics Corporation

Jon Lieber  Chief Financial Officer, Histogenics Corporation

Lawrence Bonassar, M.D. Scientific Advisory Board, Histogenics Corporation, Professor in the Meinig School, of Biomedical Engineering and the Sibley School of Mechanical and Aerospace Engineering at Cornell University

Dr. Deryk Jones, M.D.    Section Head of Sports Medicine and Cartilage Restoration at the Ochsner Sports Medicine Institute


Dr. Dean Taylor, M.D.  Dir, of the Duke Sports Medicine Fellowship Program, Director of the Duke School of Medicine Leadership Education and Development (LEAD) Curriculum, Team Physician, and Chairman of the Feagin Leadership Program

Analysts and institutional investors seeking more information about this event should contact Amanda Prior by phone or email: aprior@lazarpartners.com, or 646-619-3147.

About Histogenics Corporation

Histogenics (Nasdaq:HSGX) is a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function.  Histogenics’ lead investigational product, NeoCart®, is designed to rebuild a patient’s own knee cartilage to treat pain at the source and may prevent a patient’s progression to osteoarthritis.  NeoCart is one of the most rigorously studied restorative cell therapies for orthopedic use.  Histogenics recently completed enrollment of its NeoCart Phase 3 clinical trial and expects to report top-line, one-year superiority data in the third quarter of 2018.  NeoCart is designed to perform like articular hyaline cartilage at the time of treatment, and as a result, may provide patients with more rapid pain relief and accelerated recovery as compared to the current standard of care. Histogenics’ technology platform has the potential to be used for a broad range of additional restorative cell therapy indications.  For more information on Histogenics and NeoCart, please visit www.histogenics.com.

Forward-Looking Statements

Various statements in this release are “forward-looking statements” under the securities laws.  Words such as, but not limited to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will,” and “would,” or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties.

Important factors that could cause actual results to differ materially from those reflected in Histogenics’ forward-looking statements include, among others,  the timing and success of Histogenics’ NeoCart Phase 3 clinical trial and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Histogenics’ Annual Report on Form 10-K for the year ended December 31, 2017 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, which are on file with the SEC and available on the SEC’s website at www.sec.gov.  In addition to the risks described above and in Histogenics’ annual report on Form 10-K and quarterly reports on Form 10-Q, current reports on Form 8-K and other filings with the SEC, other unknown or unpredictable factors also could affect Histogenics’ results.

There can be no assurance that the actual results or developments anticipated by Histogenics will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Histogenics.  Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.
All written and verbal forward-looking statements attributable to Histogenics or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein.  Histogenics cautions investors not to rely too heavily on the forward-looking statements Histogenics makes or that are made on its behalf.  The information in this release and that provided at the Investor Day is provided only as of the date of this release or the date of the Investor Day, and Histogenics undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Investor Relations
Tel: +1 (781) 547-7909
InvestorRelations@histogenics.com

Primary Logo

Source: Histogenics Corporation